Interim results from the phase III IMmotion151 study to assess a combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) for advanced or metastatic renal cell carcinoma (RCC) have been reported to have improved progression-free survival (PFS), compared to sunitinib (Sutent) as a first-line treatment.

The researchers said that the combination provided a statistically significant and clinically meaningful reduction in the risk of worsening disease or death in people with PD-L1 positive RCC. In addition, the safety of the atezolizumab plus bevacizumab combination “appeared consistent” with that of the individual medicines and what was previously reported in the phase II IMmotion150 study.

Specific results from the IMmotion151 study will be presented next year at a medical congress.

Read more in Pharma Times here